Fig. 1: Treatment rate per 10 million inhabitants for the top 25 countries by treatment type; allogeneic and autologous HCT and CAR-T, by donor type and by four selected diseases in 2022. | Bone Marrow Transplantation

Fig. 1: Treatment rate per 10 million inhabitants for the top 25 countries by treatment type; allogeneic and autologous HCT and CAR-T, by donor type and by four selected diseases in 2022.

From: Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT

Fig. 1Fig. 1

a Allogeneic HCT (all transplants). b Autologous HCT (all transplants). c CAR-T treatment (patients). d HLA identical sibling HCT (all transplants). e Unrelated HCT (all transplants). f Haploidentical family HCT (all transplants). g Cord blood HCT all donor types (all transplants). h Acute myeloid leukemia in 1st complete remission (1st transplant). i Myelodysplastic syndrome (1st transplant). j Myeloproliferative neoplasm (1st transplant). k Bone marrow failure (1st transplant).

Back to article page